Nevakar Injectables Announces the Launch of Ready-to-Use Ephedrine Injection Vials

Mar 28, 2022 | NevakarInjectables

Bridgewater, NJ, USA, March 28, 2022 – Nevakar Injectables Inc., a biopharmaceutical company developing multiple sterile injectable products for use in the critical and ambulatory care settings, announced today the launch of its ready-to-use Ephedrine Sulfate...

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance

Mar 9, 2022 | Vyluma

Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance

Mar 9, 2022 | NevakarInjectables

Bridgewater, NJ, USA, March 9, 2022 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, announced today that it has closed on $12 million in convertible notes with both existing and new investors....

VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS

Oct 7, 2021 | Vyluma

Bridgewater, NJ (October 7, 2021) – Vyluma Inc. and MyMyopiaTM (MyMyopia.com) are excited to announce new tools and resources to support the International Agency for the Prevention of Blindness (IAPB) World Sight Day, a global event to draw attention to blindness and...

VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

May 25, 2021 | Vyluma

Bridgewater, NJ (May 25, 2021) – Vyluma Inc. announces its establishment as a wholly owned subsidiary of Nevakar Inc., focusing on pharmaceutical ophthalmic solutions. The robust pipeline of novel therapies is led by NVK002, a pharmaceutical atropine eyedrop to slow...

NEVAKAR INC. ANNOUNCES FORMATION OF NEVAKAR INJECTABLES

May 25, 2021 | NevakarInjectables

Bridgewater, NJ (May 25, 2021) – Nevakar Inc. (“Nevakar”), a privately held biopharmaceutical company, today announces the establishment of Nevakar Injectables Inc., a newly formed company with an established portfolio of products focused on critical patient care,...

Industry Focus: A Look at Nevakar

Mar 1, 2021 | NevakarInjectables

By JASON J. NICHOLS, OD, MPH, PHD View the article | CLICK HERE Dr. Puri, please tell us about your company in terms of its history and direction...

NEVAKAR AND THÉA ENTER INTO LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF NVK002 (ATROPINE FOR THE TREATMENT OF THE PROGRESSION OF MYOPIA IN CHILDREN) IN EUROPE

Jan 28, 2021 | Vyluma

Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...

Nevakar Announces First Subject Dosed in its Phase 3 Clinical Trial of NVK002 for the Treatment of Myopia in Children

Jan 28, 2021 | Vyluma

Bridgewater, NJ, USA and Clermont-Ferrand, France, January 28, 2021 – Nevakar Inc. (“Nevakar”), a biopharmaceutical company developing multiple assets in the ophthalmic and injectable areas, and Laboratoires Théa (“Théa”) announced today that they recently entered...

American Academy of ophthalmology leads global initiative to address worldwide myopia epidemic

Nov 11, 2020 | Vyluma

SAN FRANCISCO – Nov. 11, 2020 – The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia,...

« Older Entries